Coming November 4: ASH publishes its abstracts and its oral and poster sessions. We’ll add the institutions presenting them as they become publicly available.

Who’s Going to ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

501 organizations at ASH 2026, a ~30,000-person meeting of hematologists and blood cancer researchers, with a large biopharma presence. As of Sep 27, 2026.

Showing 1–2 of 501 organizations

Organization	ASH 2026 Attendance
Memorial Sloan Kettering Cancer Center New York, NY
mskcc.org Hospitals & cancer centres NCI-designated comprehensive cancer center in New York City combining cancer care, research and education.	Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Sheraton New Orleans · Napoleon Ballroom CD Leukemias Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Sheraton New Orleans · Napoleon Ballroom CD Lymphoma · New drugs Symposium Fri Dec 11 11:00am–2:00pm CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies Shared decision-making in chronic lymphocytic leukemia, using biomarker testing to choose among fixed-duration, continuous, and newer targeted treatments. Symposium hosted by Decera Clinical Education Convention Center · 243-245 Lymphoma Symposium Fri Dec 11 11:00am–2:00pm CML Treatment Continuum: Optimizing Therapy Selection, Molecular Monitoring, And Long-Term Quality of Life First-line drug choice, resistance, long-term side effects, and treatment-free remission in chronic myeloid leukemia, plus pipeline agents. Convention Center · Great Hall BC Leukemias Symposium Fri Dec 11 3:00pm–6:00pm Immune Therapy for Myeloma: From CAR T and T-Cell Engagers to Community Care Sequencing CAR-T and T-cell engagers for relapsed myeloma, when to refer, managing toxicity, and options after B-cell maturation antigen therapy fails. Convention Center · 343-345 Myeloma · Cell & gene Symposium Fri Dec 11 3:00pm–6:00pm Live Tumor Board: Advancing Clinical Competence in Primary CNS Lymphoma — Navigating Molecular Pathways and Emerging Therapies Treating primary central nervous system lymphoma, from methotrexate-based induction and consolidation choices to new drugs aimed at its signaling mutations. Convention Center · La Nouvelle C Lymphoma Symposium Fri Dec 11 11:00am–2:00pm Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease Diagnosing systemic mastocytosis, separating indolent from advanced disease, preventing anaphylaxis, and choosing between symptom control and Kit-targeted drugs. Symposium hosted by Decera Clinical Education Convention Center · 265-268 Leukemias Session Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies How to design clinical trials that alter the gut microbiome in blood cancers, including fecal microbiota transplants to prevent graft-versus-host disease. Blood biology Talk Part of Scientific Symposium: Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies Dietary and Prebiotic Intervention Strategies Changing gut bacteria through diet and prebiotic fiber, the evidence linking food to patient outcomes, and how to design rigorous nutrition trials. Blood biology Talk Part of Scientific Symposium: Designing Microbiome-Directed Interventional Trials in Hematologic Malignancies Live Bacterial Therapeutic Intervention Strategies Giving patients defined mixtures of live bacteria to reshape the gut and cut infections after a donor stem cell transplant. Blood biology Talk Part of Scientific Symposium: Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS Spatial Niches within the AML/MDS Bone Marrow Immune Microenvironment Leukemias · AI & data Talk Part of Scientific Program: JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy Novel Uses of RNA as Therapeutics Synthetic RNAs that exploit faulty splicing to kill cancer cells with splicing-factor mutations, and mRNA vaccines against mis-spliced protein fragments. Blood biology · Leukemias Session Advancing Personalized Care in Classic Hodgkin Lymphoma Tailoring classic Hodgkin lymphoma treatment to risk, response and circulating tumor DNA to cure with less toxicity, plus personalized follow-up care. Lymphoma Talk Part of Education Program: Advancing Personalized Care in Classic Hodgkin Lymphoma Therapeutic Approaches for Relapsed/Refractory Hodgkin Lymphoma in a Rapidly Evolving Treatment Landscape Lymphoma Talk Part of Education Program: Chronic Lymphocytic Leukemia - From Clonal Evolution to Novel Therapies A Clinical Perspective on Clonal Evolution in Chronic Lymphocytic Leukemia Lymphoma Talk Part of Education Program: Diffuse Large B-cell Lymphoma Bispecific Antibodies and Cellular Therapies for Diffuse Large B-Cell Lymphoma CAR-T cells and bispecific antibodies for diffuse large B-cell lymphoma, covering efficacy, side effects, patient selection, sequencing, and drugs in development. Lymphoma Talk Part of Education Program: Driving CARs Safely- Preventing and Managing Intermediate and Long-Term CAR-T Toxicity Immune Determinants of Infections after CAR T- Cell Therapy: A Framework for Prevention and Management Infection risk after CAR-T cell therapy, traced from early immune damage to lasting antibody deficits, and how to prevent infections at each stage. Cell & gene Talk Part of Education Program: The Golden Era of ALL Management: Rapid Advances Across the Age Spectrum Acute Lymphoblastic Leukemia in Adolescents and Young Adults: Improving Outcomes Beyond the Use of Two Pediatric Regimens Raising cure rates for teens and young adults with acute lymphoblastic leukemia by adding immunotherapy to pediatric-style regimens and limiting lasting harm. Leukemias Session From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice Case studies showing how real-world multiple myeloma data reveal treatment patterns, outcomes in underrepresented groups, and care gaps, along with their limits. Myeloma · AI & data Talk Part of Special-Interest Session: From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice Panel Discussion, Audience Q&A, and Closing Remarks Myeloma · AI & data Talk Part of Special-Interest Session: From Real-World Evidence to Real-World Impact: Translating Multiple Myeloma Data into Clinical Practice Welcome and Opening Remarks Myeloma · AI & data Session The AI Colleague: Promise, Peril, and Practice in Hematology Generative AI in hematology, from chatbot tools usable today to autonomous agents, and safeguards for reliability, bias, and human oversight. AI & data Talk Part of Special-Interest Session: Training Program Directors Workshop Artificial Intelligence for Program Directors (Part 2) Talk From Splicing Mutations to Cancer Neoantigens: A Decade of Targeting RNA Biology in Leukemia Leukemias · Blood biology
Dana-Farber Cancer Institute Boston, MA
dana-farber.org Hospitals & cancer centres Harvard-affiliated cancer treatment and research center in Boston, Massachusetts.	Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Symposium hosted by PRIME Education Convention Center · R02-R05 Lymphoma · New drugs Symposium Fri Dec 11 11:00am–2:00pm Cases and Conversations™: Precision Care in BPDCN—Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies Diagnosing blastic plasmacytoid dendritic cell neoplasm and treating it with drugs aimed at the interleukin-3 receptor, while managing capillary leak syndrome. Convention Center · La Nouvelle A-B Leukemias Symposium Fri Dec 11 11:00am–2:00pm Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making Using tests for isocitrate dehydrogenase and Flt3 mutations to guide targeted therapy choices in acute myeloid leukemia. Convention Center · 343-345 Leukemias Symposium Fri Dec 11 3:00pm–6:00pm FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New STandards for Frontline Treatment Time-limited frontline chronic lymphocytic leukemia treatment pairing Bruton tyrosine kinase and Bcl-2 inhibitors, tailored to patient goals and risk. Symposium hosted by PeerView Institute for Medical Education Hilton New Orleans Riverside · Grand Ballroom CD Lymphoma · New drugs Symposium Fri Dec 11 7:00am–10:00am MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum Managing myelodysplastic neoplasms across their spectrum, from clonal hematopoiesis and lower- and higher-risk disease to overlap syndromes and leukemia. Convention Center · 208-210 Leukemias Symposium Fri Dec 11 7:00pm–10:00pm Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia Pediatric-style regimens, asparaginase, immunotherapy, and CAR-T for teens and young adults with acute lymphoblastic leukemia, plus their psychosocial needs. Convention Center · 343-345 Leukemias Symposium Fri Dec 11 11:00am–2:00pm Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies Mantle cell lymphoma care built on Bruton tyrosine kinase inhibitors up front, with newer kinase and Bcl-2 inhibitors or CAR-T after relapse. Symposium hosted by PeerView Institute for Medical Education Hilton New Orleans Riverside · Grand Ballroom AB Lymphoma · New drugs Symposium Fri Dec 11 11:00am–2:00pm The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care Cereblon-modulating protein degraders for relapsed myeloma, from biology and trial data to sequencing, neutropenia management, and residual disease testing. Convention Center · 217-219 Myeloma · New drugs Session Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS Single-cell and spatial maps of bone marrow in acute myeloid leukemia and myelodysplastic neoplasms, showing how immune cell niches help tumors evade immunity. Leukemias · AI & data Session Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward Old and new tools, from biochemistry and mouse models to spatial gene mapping and AI, revealing weak points and treatment biomarkers in multiple myeloma. Myeloma · Blood biology Talk Part of Scientific Program: Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function Structural biology uncovered a second route for destroying the transcription factors multiple myeloma depends on, making that pathway a possible drug target. Myeloma · Blood biology Talk Part of Scientific Spotlight: CAR-T Manufacturing Across Nations: From Low-to-Middle-Income Academic Platforms to Frontier Innovations in Global Access From Frontier to Field: Manufacturing Innovations That Could Lower Barriers to CAR-T Access in LMICs Manufacturing advances from wealthy countries that could make CAR-T therapy cheaper and easier to deliver in low- and middle-income countries. Cell & gene · Patient care Talk Part of Education Program: A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation Targeting Acute and Chronic GVHD with Effective New Therapies Recently approved treatments for steroid-resistant acute and chronic graft-versus-host disease, including ruxolitinib, belumosudil, axatilimab and stromal cells. Cell & gene Talk Part of Education Program: Classical Hematology: Innovation and Technology to Match Supply and Demand Dealing with Workforce Challenges in Classical Hematology What drives the shortage of specialists in non-cancer blood disorders, and early results from efforts to close the gap. Patient care · AI & data Talk Part of Education Program: Navigating the Treatment Landscape of CNS Lymphomas The Role of CAR T-Cell Therapy, Novel Targeted Agents, and Emerging Therapies in CNS Lymphomas Lymphoma Talk Part of Special-Interest Session: Treating Fairly Rounds Lunch Challenges and Opportunities with Healthcare Reform (Perspective 2) Patient care Session Announcement of Awards: William Dameshek Prize, Janet Rowley Basic Science Medal, and Helen M. Ranney Clinical and Translational Science Medal Plenary Part of Marquee Session: E. Donnall Thomas Lecture and Prize Leveraging the Biology of the MLL (KMT2A) Complex to Discover New Therapies for Leukemia Leukemias · Blood biology

Instantly find 20 buyers from organizations at ASH 2026

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

What conference is this?

The ASH Annual Meeting and Exposition is the yearly meeting of the American Society of Hematology, the world’s largest professional society for blood disorders and blood cancers. ASH 2026 — its 68th meeting — runs December 12–15, 2026 at the Ernest N. Morial Convention Center in New Orleans, with industry satellite symposia the day before, bringing together hematologists, blood cancer researchers, transplant and cell-therapy teams, and the drug, diagnostics and tools companies that serve them.

What is in this guide?

Every organization we can place at ASH 2026: the institutions of 490 invited speakers, chairs and satellite-symposium faculty from ASH’s published program (110 invited sessions and 52 Friday satellite symposia), the 59 companies and education providers that fund or run those symposia, and the 271 exhibitors with their booth numbers — 501 organizations in one list. People appear as credentials, never by name.

How are organizations typed?

By the role an organization plays in hematology: universities and research institutes, hospitals and cancer centres, and government and non-profit bodies (agencies, blood services, foundations, patient advocates and societies); large pharma and biotech drug developers; then the suppliers — research tools, devices, diagnostics and software, and CROs, medical education companies and other services. Topics come from each session’s own title, or from an exhibitor’s own profile.

How current is it?

Pulled from ASH’s published program pages, the Friday Satellite Symposia listing and the exhibitor list on September 27, 2026. ASH publishes its abstracts and oral and poster sessions on November 4 and its product and industry theaters in mid-November — this guide adds the organizations presenting them as they become publicly available. Exhibit-hall hours are ASH’s published “Exhibits Open” times.

Organizations with their own page

356 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction